Vedolizumab in IBD – lessons from real-world experience; a systematic review and pooled analysis.

Vedolizumab in IBD – lessons from real-world experience; a systematic review and pooled analysis. J Crohns Colitis. 2017 Oct 25;: Authors: Engel T, Ungar B, Yung DE, Ben-Horin S, Eliakim R, Kopylov U Abstract Background: Vedolizumab (VDZ) is an anti-integrin monoclonal antibody effective in ulcerative colitis (UC) and Crohn’s disease (CD). Several real-world experience (RWE) studies with VDZ were published to date. The aim of this systematic review was to summarize the available real-life experience with VDZ. Methods: We performed a systematic review of the available RWE studies of VDZ…

Read More

Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy.

Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy. J Crohns Colitis. 2017 Jul 12;: Authors: Ferrante M, de Buck van Overstraeten A, Schils N, Moens A, Van Assche G, Wolthuis A, Vermeire S, D’Hoore A Abstract Background and Aims: Preoperative use of vedolizumab has been associated with increased short-term postoperative infectious complications. We assessed this risk in a single-centre cohort of patients with ulcerative colitis undergoing colectomy. Methods: Chart review was performed for all colectomies between 2006 and 2016. Short-term…

Read More

Long-term Combination Therapy with Anti-TNF plus Vedolizumab Induces and Maintains Remission in Therapy-refractory Ulcerative Colitis.

Long-term Combination Therapy with Anti-TNF plus Vedolizumab Induces and Maintains Remission in Therapy-refractory Ulcerative Colitis. Am J Gastroenterol. 2017 Oct;112(10):1621-1623 Authors: Fischer S, Rath T, Geppert CI, Manger B, Schett G, Neurath MF, Atreya R PMID: 28978957 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28978957?dopt=Abstract

Read More

Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease.

Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2017 Aug 31;: Authors: Lahat A, Shitrit AB, Naftali T, Milgrom Y, Elyakim R, Goldin E, Levhar N, Selinger L, Zuker T, Fudim E, Picard O, Yavzori M, Ben-Horin S Abstract Introduction: There are no data on the transfer of vedolizumab in breast milk of nursing mothers. We aimed to assess the presence of vedolizumab in breast milk of nursing inflammatory bowel disease (IBD) patients. Methods: This was a prospective observational study of vedolizumab-treated breast-feeding…

Read More

Surgical Outcomes in Vedolizumab-Treated Patients with Ulcerative Colitis.

Surgical Outcomes in Vedolizumab-Treated Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2017 Aug 29;: Authors: Lightner AL, McKenna NP, Moncrief S, Pemberton JH, Raffals LE, Mathis KL Abstract BACKGROUND: Surgical outcomes and pouch outcomes in the setting of vedolizumab remains poorly understood. We sought to determine the rate of 30-day postoperative surgical infectious complications and pouch-specific complications among patients with ulcerative colitis (UC) who received vedolizumab within 12 weeks of surgery. METHODS: A retrospective chart review between 5/1/2014 and 12/31/2016 of all adult patients with UC who underwent an abdominal…

Read More

Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab.

Related Articles Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Jul 18;: Authors: Yamada A, Komaki Y, Patel N, Komaki F, Aelvoet AS, Tran AL, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A Abstract OBJECTIVES: Vedolizumab is increasingly used to treat patients with ulcerative colitis (UC) and Crohn’s disease (CD), however, its safety during the perioperative period remains unclear. We compared the 30-day postoperative complications among patients treated preoperatively…

Read More

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN.

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN. J Crohns Colitis. 2017 Jun 09;: Authors: Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovsky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi J, Richmond L, Bronsky J, Friedman M, Turner D Abstract Background: Vedolizumab, an anti-integrin antibody, has proven to be effective in adults with Inflammatory Bowel Disease (IBD), but…

Read More

One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.

Related Articles One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017 Jun 08;: Authors: Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Gagniere C, Bouhnik Y, OBSERV-IBD study group and the GETAID Abstract BACKGROUND: We recently showed that vedolizumab…

Read More
<< Go Back